SciBac Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SciBac Inc. - overview
Established
2015
Location
Burlingame, CA, US
Primary Industry
Pharmaceuticals
About
SciBac Inc. is a biotechnology company focused on developing innovative software solutions and products that enhance operational efficiency and analytics for businesses in various sectors. Founded in 2015 in Burlingame, US, SciBac Inc. specializes in delivering technological solutions tailored to operational needs.
The company was co-founded by Anthony Cann, Derik Twomey, and Jeanette Mucha, who also serves as CEO. In July 2018, SciBac Inc. raised USD 3. 76 mn in Grant funding led by CARB-X, marking a significant milestone for the firm.
SciBac Inc. offers a comprehensive suite of software solutions designed to enhance operational efficiency and analytics for businesses. These offerings serve small to medium-sized enterprises (SMEs) and larger corporations across sectors like finance, healthcare, and logistics. The company operates in North America and Europe, meeting the growing demand for innovative operational solutions.
SciBac Inc. generates revenue primarily through subscription-based models, allowing clients to access their software solutions via annual or monthly subscriptions that are customized for various industry needs. Revenue is bolstered through strategic partnerships that facilitate product distribution, with pricing determined by the features and scale of services selected by clients. SciBac Inc.
aims to leverage the recent USD 3. 76 mn Grant funding raised in July 2018 to support the development of new products and enhance its market reach. The company plans to expand into additional markets, specifically targeting regions in Europe and Asia by 2023, while developing new software solutions to meet evolving client needs.
Current Investors
Breakout Ventures, CARB-X
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.scibac.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.